BRIEF—Takeda to sell Brazil subsidiary

Japan’s Takeda Pharmaceutical has signed an agreement with Novamed Fabricação de Produtos Farmacêuticos to sell/divest all shares, and all its assets in its 110%-owned Brazilian subsidiary Multilab Indústria e Comércio de Produtos Farmacêuticos to Novamed.

The deal’s value is not disclosed.

Takeda is committed to continuing to help meet the unmet needs of patients in Brazil and to maintaining its ‘best-in-class’ position in its core therapeutic areas, including gastroenterology and oncology.

Taking into careful consideration the future development of Multilab's business, Takeda is confident that Novamed, part of the NC Group which owns some of the largest pharmaceutical companies in Brazil, will develop the future business of Multilab by leveraging the synergies of both companies.

The impact of the divestment on Takeda's consolidated results for fiscal year 2017 is minimal, the company stated.